{"name":"Cytokinetics","slug":"cytokinetics","ticker":"CYTK","exchange":"NASDAQ","domain":"cytokinetics.com","description":"Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.","hq":"South San Francisco, CA","founded":0,"employees":"673","ceo":"Robert I. Blum","sector":"Cardiovascular","stockPrice":66.48,"stockChange":1,"stockChangePercent":1.53,"marketCap":"$8.2B","metrics":{"revenue":13368000,"revenueGrowth":4.9,"grossMargin":0,"rdSpend":416026000,"netIncome":-784955000,"cash":882220992,"dividendYield":0,"peRatio":-13.5,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Omecamtiv Mecarbil patent cliff ($1.4B at risk)","drug":"Omecamtiv Mecarbil","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"Aficamten patent cliff ($2.5B at risk)","drug":"Aficamten","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"CK-2017357","genericName":"CK-2017357","slug":"ck-2017357","indication":"Hypertrophic cardiomyopathy","status":"phase_2"},{"name":"Omecamtiv Mecarbil (OM)","genericName":"Omecamtiv Mecarbil (OM)","slug":"omecamtiv-mecarbil-om","indication":"Heart failure with reduced ejection fraction (HFrEF)","status":"phase_3"},{"name":"Placebo to match aficamten","genericName":"Placebo to match aficamten","slug":"placebo-to-match-aficamten","indication":"Matching placebo for aficamten trials in hypertrophic cardiomyopathy","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AMG 423","genericName":"AMG 423","slug":"amg-423","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AMG 423","genericName":"AMG 423","slug":"amg-423","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CK-2017357","genericName":"CK-2017357","slug":"ck-2017357","phase":"phase_2","mechanism":"CK-2017357 is a cardiac myosin inhibitor that increases cardiac contractility.","indications":["Hypertrophic cardiomyopathy"],"catalyst":""},{"name":"Omecamtiv Mecarbil (OM)","genericName":"Omecamtiv Mecarbil (OM)","slug":"omecamtiv-mecarbil-om","phase":"phase_3","mechanism":"Omecamtiv mecarbil is a cardiac myosin activator that directly enhances the force of heart muscle contraction by increasing the number of myosin heads that generate force during systole.","indications":["Heart failure with reduced ejection fraction (HFrEF)","Acute heart failure"],"catalyst":""},{"name":"Placebo to match aficamten","genericName":"Placebo to match aficamten","slug":"placebo-to-match-aficamten","phase":"phase_3","mechanism":"This is an inert placebo formulation designed to match the physical and sensory characteristics of aficamten for blinded clinical trial purposes.","indications":["Matching placebo for aficamten trials in hypertrophic cardiomyopathy"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Cytokinetics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Cytokinetics reported its financial results for the fourth quarter and full year 2023, with net loss of $63.4 million and $234.5 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-12-19","type":"deal","headline":"Cytokinetics Announces Collaboration with Amgen to Develop and Commercialize Omecamtiv Mecarbil","summary":"Cytokinetics announced a collaboration with Amgen to develop and commercialize Omecamtiv Mecarbil, a novel cardiac myosin inhibitor for the treatment of heart failure.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"Cytokinetics Announces Positive Topline Results from Phase 2 Trial of Aficamten in Patients with Heart Failure","summary":"Cytokinetics announced positive topline results from a phase 2 trial of Aficamten in patients with heart failure, demonstrating a statistically significant reduction in NT-proBNP levels.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBXMnVuV19DMzZQNDkybnY1MVp3NjNJWEFpYVNySzlaX2lycHUyLXJNOE4xWDluUWljNU1wXzE5dzk4MzI3M2VwXzBUYjd3VWtJSEE?oc=5","date":"2026-04-07","type":"pipeline","source":"Yahoo Finance Australia","summary":"Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance Australia","headline":"Cytokinetics, Incorporated (CYTK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-26","type":"earnings","source":"simplywall.st","summary":"Cytokinetics (CYTK) Quarterly Loss Of US$183 Million Reinforces Bearish Profitability Concerns - simplywall.st","headline":"Cytokinetics (CYTK) Quarterly Loss Of US$183 Million Reinforces Bearish Profitability Concerns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPdTVKMWl1UVpxQ3R3bDFzY2dfWXF4VjMzVjhwSHNCQ1JXcUJNOTl0SGVjeV96YnhXN242dWpMWllXdTVGZVZHbkFwdlpXNzEzd0lqOXp5dWdiWWVZM1czTk9NMUliYzZLckVJcG1xRXpYWmRuZWxwSl9aSVk3c21GdFktTkxpX1RHMmlKMVIwbDZDT0NTdnUzcVdLdnF5N3FScW5z?oc=5","date":"2026-02-25","type":"earnings","source":"Finviz","summary":"CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Finviz","headline":"CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNVURrSVVXaXVkUElIOURKQTJGcWhtU0ZKa0lXV2lGVXlCVnNGaDBNc252ZGxBbFdoNWFid0VKVk1PYUVia0dIdVF0NTJiTlYyTFptd0RsaktnZmpLblVZRk9YSXhMMVZKUkRDSjl2MnpOVnF2NzJqbU51bTVjMm5zOXd4b2FJNDQ?oc=5","date":"2026-02-17","type":"pipeline","source":"The Pharma Letter","summary":"Cytokinetics wins EC nod for Myqorzo - The Pharma Letter","headline":"Cytokinetics wins EC nod for Myqorzo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOSVNFcnF0b2V5YksxS2plNWgxVWxIdEdSSlY0bWNRcUlTWHhjbGhJUjRwNDNWazNDS1NuNWJ1RlY2V1I2MTFNZ3AyTGZPTTk2VlhSNTZ1UjdiSTNYTDBGSXVLX2JCNURFNm1STjIxWVp2RjJueWlsMlNmamhFRzJ1QW9PQVd4MjNEYlhTVlJrSFVjVXVvTVJyS9IBoAFBVV95cUxNc0s0eDlQTW8xZG1ES0pXU0pCQ0xZSlA3X3JTaVhiWEw3X2hvdWNmeTNKTVpEOE82MS1UUTNuNzR0c25BSkNnSXlyWWdSSHhaREhzRk14TVRWZ2sxZjZtZGpkVDNqMF9QUEhTazcxQUV1RHlHLTQxTkt4WUxHRlVmVWs5QmpPSDFSTS15QmkzLTN1OHNnVzVsYTQxSjRJUzdE?oc=5","date":"2026-02-03","type":"pipeline","source":"Insider Monkey","summary":"Cytokinetics, Incorporated (CYTK): A Bull Case Theory - Insider Monkey","headline":"Cytokinetics, Incorporated (CYTK): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPNTN6QzFYeGVSY2t4aFk5R2laaFRxbElwR1Y4eEh1dGJrdUJESEJjM0hqRzNxbkExeTFObjA0QzYzbjRZbWVKNTY2YlZrNFJPU3UwVVhldzNKSk5MTVdhSi1kLUJwVFNqS3VCLS0yZ0tZMjgwSW5sMXVXSW9hZ2NLMFpvR05hZ283VHFYb291VTc?oc=5","date":"2026-01-27","type":"pipeline","source":"The Pharma Letter","summary":"Cytokinetics launches first product, Myqorzo - The Pharma Letter","headline":"Cytokinetics launches first product, Myqorzo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPa2EzeDFNVHpyT3RMSWZwbGNsak5TWnZLSVFSblNEcXZ0UzJzenFzUTNkaFdFci1McTA0bFlIM0NBWm5vOWltb3hYSU9QdFVUZV9ubExQVFhBX3FSSHBWTHJERnJQMElBNU9lR0VHSnlCc2pUT3VOOWF0eW1QWmktVUNDWnJ3OVVYREV1UVd6Z2I5RWJnMVNIVTVQcS0yOFZXaGtKSUc4ekNweUtUeGZZN0NPajZfTlFfdnBSRA?oc=5","date":"2026-01-27","type":"pipeline","source":"Stock Titan","summary":"Olympian Sydney McLaughlin-Levrone on hypertrophic cardiomyopathy at home - Stock Titan","headline":"Olympian Sydney McLaughlin-Levrone on hypertrophic cardiomyopathy at home","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOYTA0djlKZFBjeWM5WXkxemZheGd0Umk4X2hvbVdRODdHRUtXSWd6aVE2bmZEVnhmcGsxNlFvTkNDalh1LVc5NUctQ3pQSTU5TkYwZm1DUTJQRjNlREtRRVZXZWpnVFJwVk9hWlFPQ2JIZmE1XzdCT01UXzlZanM5VlJ0UGk5VzM2V2lCZk8xQ2g5ZldZNG8xWmpZSWY?oc=5","date":"2026-01-01","type":"pipeline","source":"TechStock²","summary":"Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next - TechStock²","headline":"Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOOC1HWUFSLUVVWmxvbFFNeThiR2J3T2NBTzFLSUF6c2N3MGN0Wk9OcjZlOWF5Rjh6N0cwUk1DSjdFSkVMdXVwSWV2aUc1d1FXakg3aDdUSFRuaDZMbnRwdTc4aXoyQnZldjNmWnU5QUhPYk4zUFA4QWZvcVp3ekZQNngxNkdLdXFtVVlrcFpTTGpZcHpHT1dLNEx0Wkc3S3lRVG9qS0RvSQ?oc=5","date":"2025-12-22","type":"regulatory","source":"Seeking Alpha","summary":"Cytokinetics: Small Label Differences With Big Commercial Stakes (CYTK) - Seeking Alpha","headline":"Cytokinetics: Small Label Differences With Big Commercial Stakes (CYTK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNMFBGWlFzZmpndEhGbldUa3BNem1jNmZjRFdzOUdJcHZhVHhSclA5UlNpdUk5YXo5ZDV4WmI3WTVhZ1NNeVNDdXN5UjlKbFZwUTVOLVpXV05pck5iZWZ1UjBFWmduRHpUOUU5N2hIaGh6d0dFOVNIVmJ3T0Y1YTFrVEhHUkFpQlRVSUY0YUJWUXR5NDRiV3YyY3AxbmhRNkhsMzVhUUNZdGZmVjVGTHJFUnlFbXpqekloaFJGS2k3U0RSZnM?oc=5","date":"2025-12-22","type":"regulatory","source":"TechStock²","summary":"Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes - TechStock²","headline":"Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes - TechStock²","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPbmxjRlBEek40dThidDRHZ085ZDZob082ajVuRzAzMFJQckJLRFlEVUFydnRrTDhUSWlaemF0WkE0UHBmN2dZTWp5X3B0bjhOUV9INkUtQzNYeF9lMWw1MnM3YS04ZUZvckphZTFpcjFRSFJpMmpjT011OWxOX2NTQjBQVHdtcDYyeE5IWjIxcW1fQU5ZcHJjd3h0TG9pVjJadi1Yel9lbDlHZW4xRzZvZUlwenpaUjdsallZ?oc=5","date":"2025-12-19","type":"regulatory","source":"reuters.com","summary":"US FDA approves Cytokinetics' heart disease drug - reuters.com","headline":"US FDA approves Cytokinetics' heart disease drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOVkVzRnoyV0p3bVBid0pqcDBFSUYyZTl2SVBac3BZRE15UC0tdkdiVFNTM09faldhU3lFZXlnN1pYWUx4cEo4aWw4XzZpVkFwV1k5Ti12ZlgxMnZxYlYyZUFqQ3BFQ3pLcktUeFY4cjd2eTFIVTVHQzhieVN2MG1OV0V0dVlHRWl4UjNZQUhFY3A1bUE4UE5taThDcE9Vbm53VElHWk1ZMHlYSGVrYXhHa0k3VGY4Qm93?oc=5","date":"2025-11-21","type":"regulatory","source":"Seeking Alpha","summary":"Cytokinetics: Approval Catalyst In December - But Risk Reward Is Not Compelling (CYTK) - Seeking Alpha","headline":"Cytokinetics: Approval Catalyst In December - But Risk Reward Is Not Compelling (CYTK)","sentiment":"positive"}],"patents":[{"drugName":"Omecamtiv Mecarbil","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Aficamten","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":2500000000}],"drugCount":4,"phaseCounts":{"phase_1":1,"phase_2":1,"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Amgen","Bristol Myers Squibb","Pfizer"],"therapeuticFocus":["Cardiovascular","Musculoskeletal"],"financials":{"source":"sec_edgar","revenue":13368000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":13368000,"period":"2017-12-31"},{"value":106407000,"period":"2016-12-31"},{"value":106407000,"period":"2016-12-31"},{"value":28658000,"period":"2015-12-31"},{"value":28658000,"period":"2015-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":416026000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-784955000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1424537000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":66.48,"previousClose":65.48,"fiftyTwoWeekHigh":70.98,"fiftyTwoWeekLow":29.31,"fiftyTwoWeekRange":"29.31 - 70.98","fiftyDayAverage":63.72,"twoHundredDayAverage":54.79,"beta":0.48,"enterpriseValue":8621322240,"forwardPE":-13.5,"priceToBook":-12.39,"priceToSales":93,"enterpriseToRevenue":97.93,"enterpriseToEbitda":-14.32,"pegRatio":0,"ebitda":-602132992,"ebitdaMargin":0,"freeCashflow":-379618752,"operatingCashflow":-510008992,"totalDebt":1438843008,"debtToEquity":0,"currentRatio":4.53,"returnOnAssets":-27.1,"returnOnEquity":0,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":17,"targetMeanPrice":92.82,"targetHighPrice":136,"targetLowPrice":67,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.1,"institutionHeldPercent":115.4,"sharesOutstanding":123162807,"floatShares":122295741,"sharesShort":15662163,"shortRatio":8.57,"shortPercentOfFloat":12.7,"epsTrailing":-6.54,"epsForward":-4.93,"revenuePerShare":0.73,"bookValue":-5.37,"officers":[{"age":61,"name":"Mr. Robert I. Blum","title":"CEO, President & Director"},{"age":55,"name":"Mr. Sung H. Lee","title":"EVP & CFO"},{"age":61,"name":"Dr. Fady Ibraham Malik FACC, M.D., Ph.D.","title":"Executive Vice President of Research & Development"},{"age":56,"name":"Mr. Andrew M. Callos","title":"Executive VP & Chief Commercial Officer"},{"age":67,"name":"Dr. James H. Sabry M.D., Ph.D.","title":"Co-Founder & Chairman of Scientific Advisory Board"},{"age":83,"name":"Dr. James A. Spudich Ph.D.","title":"Co-Founder & Member of Scientific Advisory Board"},{"age":null,"name":"Mr. Jeff  Lotz","title":"Vice President of Sales & Operations"},{"age":null,"name":"Ms. Holly  Laughlin","title":"VP of Accounting & Corporate Controller"}],"industry":"Biotechnology","irWebsite":"http://phx.corporate-ir.net/phoenix.zhtml?c=142156&p=irol-IRHome","website":"https://www.cytokinetics.com","phone":"650 624 3000"}}